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Abstract
Molecular analysis of infectious processes in bacteria normally involves construction of isogenic mutants that can then be
compared to wild type in an animal model. Pathogenesis and antimicrobial studies are complicated by variability between
animals and the need to sacrifice individual animals at specific time points. Live animal imaging allows real-time analysis of
infections without the need to sacrifice animals, allowing quantitative data to be collected at multiple time points in all
organs simultaneously. However, imaging has not previously allowed simultaneous imaging of both mutant and wild type
strains of mycobacteria in the same animal. We address this problem by using both firefly (Photinus pyralis) and click beetle
(Pyrophorus plagiophthalamus) red luciferases, which emit distinct bioluminescent spectra, allowing simultaneous imaging
of two different mycobacterial strains during infection. We also demonstrate that these same bioluminescence reporters can
be used to evaluate therapeutic efficacy in real-time, greatly facilitating our ability to screen novel antibiotics as they are
developed. Due to the slow growth rate of mycobacteria, novel imaging technologies are a pressing need, since they can
they can impact the rate of development of new therapeutics as well as improving our understanding of virulence
mechanisms and the evaluation of novel vaccine candidates.
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Introduction
Tuberculosis (TB) is a major public health problem, with over
eight million new cases and 1.3 million deaths attributed to TB in
2012 [1]. Tuberculosis is a pulmonary infection that is acquired
through inhalation of bacteria arising from infected individuals.
The absence of a candidate with clearly superior efficacy to the
current vaccine [2], an attenuated form of Mycobacterium bovis,
bacillus Calmette-Gue´rin (BCG), and the unsatisfactory results of a
recent anti-tuberculosis vaccine trial [3] demonstrate that addi-
tional strategies for rapid evaluation of vaccines are greatly
needed. Vaccine efficacy trials would be facilitated by the ability to
evaluate the challenge dose in real-time, as could be accomplished
with imaging, rather than waiting the one month required for
determination of bacterial load by colony forming units (cfu) with
M. tuberculosis. Due to the difficulty of clearing M. tuberculosis
from an infected host, successful treatment requires multiple
antibiotics that must be taken for six months or more [1]. Such a
long treatment time leads to patient non-compliance and has
resulted in emergence of multi-drug and extensively drug resistant
M. tuberculosis strains. The slow growth rate of M. tuberculosis
[4,5] makes virulence studies extremely slow in comparison to
other pathogens, resulting in limited availability of information
regarding mechanisms of disease establishment and progression.
New tools for the study of TB in animal models are needed to
facilitate development of TB prevention and treatment strategies.
Our group has been developing imaging technologies to analyze
the dynamics of M. tuberculosis infections. We have found that
tdTomato fluorescent protein labelled M. tuberculosis can be
detected in the lungs of infected mice, but not green fluorescent
protein (GFP) labelled bacteria, most likely due to the shorter
emission wavelength of GFP [6,7]. The number of bacteria
required for detection by tdTomato is 105 cfu, a relatively high
number as compared to the infectious dose of 1–10 cfu.
Interestingly, we have also used tdTomato labelled BCG infected
mice to assess the efficacy of microendoscopy for detection [8],
significantly improving limits of detection. In the case of M.
tuberculosis, secreted b-lactamase BlaC can be used in reporter
enzyme fluorescence (REF) to cleave fluorogenic substrates made
using fluorescent dyes linked to quenchers via a b-lactam ring
[9,10]. REF allows the detection of M. tuberculosis in live animals
without the need to genetically modify the bacteria, enabling it to
be used to detectM. tuberculosis in clinical samples [11]. Although
fluorescence systems have shown great promise, bioluminescence
has the potential to allow rapid evaluation of bacterial viability and
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avoids the need for removal of autofluorescence normally seen in
mammalian tissues.
Bacterial and eukaryotic bioluminescence systems have been
used as reporters in bacteria [12–31]. The bacterial biolumines-
cence reporter systems are based on expression of the bacterial
luxCDABE operon to produce a light signal [32]. No exogenous
substrate is required, since the luxCDE genes code for substrate
synthesis enzymes [33]. The Photorhabdus luminescens luciferase
system [34] has been expressed from a plasmid in many different
genera of bacteria, including strains of Salmonella that were first
used to demonstrate non-invasive optical imaging in vivo [35].
Modified versions of this lux operon have been used in
mycobacteria [16]. Expression of only the enzymatically active
luciferase, luxAB, from Vibrio harveyi, has also been used in
mycobacteria to study bacterial dissemination and antibiotic
treatment efficacy, but requires delivery of an aldehyde that is
poorly membrane permeable [19,30,31]. The eukaryotic biolumi-
nescence systems take advantage of luciferases from insects,
including the North American firefly Photinus pyralis and the
click beetle Pyrophorus plagiophthalamus [24], and use a luciferin
substrate that has good membrane permeability. Expression of
firefly luciferase in mycobacteria has been used in vitro to study
antibiotic resistance in different strains [12–16,27,36,37], as well as
in vivo [15,18,19,30,38]. Possibly the reasons that luciferases are
commonly used for antimicrobial studies is their rapid loss of signal
due to the requirement of ATP for light production, in contrast to
fluorescent proteins that are very stable and fluorogenic probes
that depend on the pharmacokinetics of the fluorescent product
for signal loss [9]. The emission spectra of the insect luciferases are
usually in the yellow-red range, compared to the bacterial
luciferases that emit in the green to blue range [24]. Light at
shorter wavelengths (e.g., blue-green) is more problematic for in
vivo imaging, since animal tissues absorb more light at
wavelengths below 600 nm [39]. Light produced by the bacteria
is absorbed by the surrounding tissues and is highly attenuated
[40]. Use of bioluminescence in mycobacteria has concentrated on
evaluating antibiotic resistance in vitro [12–16,27,31,36,37] or in
vivo [15,18,19,30,38].
We have developed optimized bioluminescence systems to study
mycobacterial infection kinetics in real-time. We chose two
luciferases, click beetle red luciferase (CBRlux) and firefly
luciferase (FFlux) that have large proportions of their emission
spectra in the far red wavelengths of light [40] making them good
optical reporters for in vivo imaging. We optimized the codon
usage of these genes for mycobacteria, and expressed both
CBRlux and FFlux from plasmids in BCG. These bioluminescent
mycobacterial strains were then used to quantify bacterial burden,
both in vitro and in animals using non-invasive optical imaging.
We show that these constructs can be used for subcutaneous
detection of 103 cfu in vivo. Moreover, the different spectra
maxima of the two luciferases allow use of mixed cultures and
quantitative differentiation of bacterial numbers expressing them,
both in vitro and in vivo, permitting simultaneous imaging of both
CBRlux and FFlux. We also demonstrate detection of these
bioluminescent bacteria in the lungs of intratracheally infected
mice and found that the signal is sensitive to antibiotic treatment.
These observations demonstrate feasibility for simultaneous
detection of multiple mycobacterial strains during infection, as
well as rapid evaluation of novel intervention strategies and
virulence assessment in animal models.
Materials and Methods
Bacterial strains and growth conditions
Strains and plasmids used in this study are listed in table 1.
BCG was grown in M-OADC-Tw made with 7H9 broth (Difco,
Detroit, MI) supplemented with 0.5% glycerol, 10% OADC (oleic
acid dextrose complex without catalase), and 0.05% Tween 80 or
Middlebrook 7H9 supplemented with 10% OADC and 15 g/liter
Bacto agar (M-OADC agar) or on 7H11 selective agar (Difco)
medium supplemented with 80 mg ml21 hygromycin. The
composition of the OADC supplement used was as described in
the Difco manual [41] with the exception that it does not contain
catalase. A stock solution of 1% (wt/vol) oleic acid is made in 0.2
N NaOH prior to adding 5 ml of the stock solution per 100 ml
final volume of OADC supplement.
In the case of growth curves, mycobacteria were inoculated at
OD600 of 0.02 into 96-well plates with or without different
concentrations of both isoniazid (INH) plus rifampin (RIF) and
incubated at 37uC. Luminescence and OD600 readings were taken
every 2 days up to 28 post inoculation with a Mithras multimode
reader (Berthold Technologies, TN). To measure luminescence of
mixed cultures, strains were inoculated at an OD600 of 0.02 and
incubated at 37uC for 10 to 14 days. The bacteria were diluted to
26108 cfu ml21 and the two strains were mixed at rations of 1:1,
10:1, 1:10, 100:1 and 1:100. Dilutions of bacterial cultures were
plated on M-OADC agar and incubated at 37uC for 3–4 weeks to
obtain cfu.
Construction of luciferase expression plasmids
CBRlux and FFlux expression plasmids were constructed by
cloning each luciferase gene between the NheI and PacI sites of
pJDC89 [42] or a derivate of pJDC89 where the Phsp60 had been
replaced by the PL5 promoter [43–45]. This vector uses the
mycobacterial pAL5000 low-copy number origin of replication,
that is stable in mycobacteria [46,47]. CBRlux and FFlux codon
sequences were optimized for expression in mycobacteria (Gen-
Script, NJ) and the resulting genes were also inserted into pJDC89
vector via the NheI and PacI sites. Codon optimized sequences
have been submitted to Genbank (accession numbers: JQ031640
for CBRlux and JQ031641 for FFlux). Expression strains were
constructed by transforming the plasmids into BCG by electropo-
ration and plating the bacteria on M-OADC agar supplemented
with 80 mg ml21 hygromycin to select for the presence of plasmid.
The presence of plasmid was confirmed in all strains by selecting
multiple colonies and screening for those that produced maximal
luminescence in the presence of 2 mM luciferin. In all cases, less
than 10-fold variation was observed between individual colonies
selected from transformants with a single construct. Luminescence
was measured in white 96-well plates containing 50 ml of each
bacteria suspended in culture medium and 50 ml of 2 mM
luciferin added to each well and luminescence measured at 10 s
post-addition and every 10 s thereafter.
Cell lines, culture conditions and macrophage infection
assays
Murine macrophage cell line J774A.1 (ATCC TIB67) was
maintained in high glucose Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) supplemented with 10% heat inactivated FBS
(Gibco) and 2 mM L-glutamine at 37uC in the presence of 5%
CO2. Cell infection assays were performed as described previously
[48]. Briefly, 56104 J774A.1 cells were seeded in white 96-well
plates for 20 h to allow formation of a monolayer. Mycobacteria
were added at multiplicities of infection (MOI) of 100, 10, 1 and
0.1 bacteria per macrophage, incubated for 30 min to allow
Dual Bioluminescence in Mycobacteria
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internalization, washed twice with pre-warmed PBS to remove
extracellular bacteria, 50 ml of complete DMEM added to each
well and luminescence was measured at 1, 2 and 7 d post-infection
in the same manner as for bacteria in culture.
Animal infections
Five- to seven-week old female BALB/C mice were used in all
experiments. Mice were housed in groups of less than five in
polycarbonate cages in a temperature, humidity and light
controlled environment and provided commercial chow and tap
water ad libitum. Mice were allowed to acclimate to the facilities
for one week prior to studies. Subcutaneous infections were carried
out by shaving the backs of mice and injecting dilutions of bacteria
subcutaneously at specific sites in the back of each mouse. The
mice were then imaged at 24 h post-infection and necropsied to
determine cfu present at the site of inoculation. Alternatively, mice
were infected intratracheally with 16106 bacteria, as described
previously [25,26]. Two mice per group, randomly allocated, were
imaged and sacrificed for necropsy to determine thresholds of
detection, correlate luminescence with cfu and compare different
luminescence constructs. Antibiotic treatment was carried out with
four mice per group, randomly allocated, by administration of RIF
plus INH intraperitoneally daily at 10 mg kg21 animal body
weight. At each time point a group of animals in each treatment
category were imaged, necropsied, lungs imaged and homoge-
nized for cfu determination by plating dilutions of tissue
homogenates. Animal use protocols were reviewed and approved
by the Institutional Animal Care and Use Committee of Texas
A&M University under AUP#2011-67.
Imaging mycobacterial infections
Imaging was performed essentially as described previously
[25,26]. Briefly, mice were anesthetized using isoflurane and
imaged using the IVIS Spectrum imaging system (PerkinElmer).
Luciferin was injected intraperitoneally between 10 and 15 min
prior to imaging to measure luminescence. Luciferin was injected
at 150 mg/kg of animal body weight. Images were acquired with
up to 5 min exposures and analysed with Living Image Software
v3.1. For some experiments, spectral algorithms were used to
differentiate signals from the two different luciferases. Images were
acquired using different emission filters from 520 nm to 720 nm
and signal quantified at each wavelength.
Statistical Analyses
All experiments were carried out in triplicate and repeated at
least two times, with similar results obtained. Data shown are for a
representative experiment. The significance of the results were
determined using the Student’s t test for pairwise comparisons or
ANOVA with the Tukey-Kramer post-hoc pairwise t test for
comparisons of three or more groups. GraphPad Prism 5 software
was used to facilitate statistical analyses. P,0.05 was considered
significant.
Results
Expression of luciferases does not impact mycobacterial
growth
Bioluminescence from luciferases can be used to track both
eukaryotic cells for cancer studies and bacterial pathogens in
animal models [15,18–26,28–30,35,49–52]. Luciferases have great
potential for tracking pathogenic mycobacteria in animal models
for rapid quantitative analysis of bacterial loads in all organs
during disease, vaccine efficacy studies and evaluation of novel
therapeutics. Firefly luciferase (FFlux, from P. pyralis) and click
beetle red luciferase (CBRlux, from P. plagiophthalamus) were
cloned into mycobacterial expression vector pJDC89 under the
Table 1. Strains and Plasmids.
Strain aGenotype Source or Reference
E. coli XL1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIq ZDM15 Tn10 (Tetr)] Stratagene
BCG Mycobacterium tuberculosis var. bovis bacillus Calmette-Gue´rin strain Pasteur Statens Serum Institute, Copenhagen, Denmark
BCG16 BCG::pJDC134 Current study
BCG18 BCG::pJDC89 Current study
BCG26 BCG::pJDC132 Current study
BCG47 BCG::pJDC181 Current study
BCG48 BCG::pJDC182 Current study
BCG51 BCG::pJDC178 Current study
BCG52 BCG::pJDC179 Current study
Plasmid Characteristics
pJDC89 Phsp60 Hyg
r oriM [42]
pJDC132 pJDC89 CBRlux Current study
pJDC134 pJDC89 FFlux Current study
pJDC178 pJDC89 PL5 optCBRlux Current study
pJDC179 pJDC89 PL5 optFFlux Current study
pJDC181 pJDC89 optCBRlux Current study
pJDC182 pJDC89 optFFlux Current study
aHyg = hygromycin, Tet = tetracycline, oriM = mycobacterial pAL5000 origin of replication [47,62], Phsp60 = promoter from 60 kDa heat shock protein [63], PL5 =
promoter from the L5 mycobacteriophage [45,64], CBRlux = click beetle red luciferase, FFlux = firefly luciferase, optCBRlux = click beetle red luciferase with all amino
acid codons modified to the optimal codons for mycobacteria, optFFlux = firefly luciferase with all amino acid codons modified to be optimal for mycobacteria.
doi:10.1371/journal.pone.0108341.t001
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control of two different constitutively active promoters; the Phsp60
promoter or the PL5 promoter [43–45]. The resulting constructs
were transformed into BCG and evaluated for growth rate and
light production over 18 days (Figure 1). Luminescence correlates
well with bacterial numbers during the exponential phase of
growth (Figure 1C). During exponential growth, the amount of
light produced increases along with bacterial numbers and
plateaus at around 8 days, which is approximately the same time
the cultures reach stationary phase. After reaching stationary
phase, light production remains relatively constant until 20 days
post inoculation. Constant light production, despite increasing
bacterial numbers, is most likely a reflection of the metabolic state
of stationary phase mycobacteria, since light production by
coleopteran luciferases is dependent on ATP [32]. Neither
luciferase had an impact on the growth rate of BCG and light
production was very similar overall for both luciferases. During log
phase there was a higher level of light production from FFlux as
compared to CBRlux (Figure 1B), which could be due to a
number of factors, including FFlux having less of a metabolic
impact on mycobacteria, allowing greater light production or
improved translation of the FFlux gene due to preferred codon
usage. These data demonstrate that expression of both CBRlux
and FFlux are well tolerated by mycobacteria and light production
correlates with bacterial numbers under most conditions, suggest-
ing that these reporters will be valuable for tracking mycobacteria
during infections.
Luciferases allow quantification of intracellular
mycobacteria
Mycobacteria are primarily considered intracellular pathogens
that can readily infect and replicate within macrophages [53,54].
Since metabolic changes could impact expression of luciferase by
mycobacteria, we examined whether a similar correlation with
bacterial numbers was observed when the bacteria are growing
within macrophages to that observed in culture. Using bacteria to
cell ratios of 0.1 to 100 in murine macrophages, we found that
both CBRlux and FFlux produced signal above background that
correlated very well (r2 = 0.96 for CBRlux, r2 = 0.92 for FFlux)
with bacterial numbers (Figure 2). This correlation is sufficient to
allow accurate quantification of bacterial numbers by lumines-
cence in the place of cfu. The level of luminescence produced was
stable out to 7 days post-infection of macrophages and both
CBRlux and FFlux produce similar levels of luminescence. We
show that intracellular growth does not significantly impact levels
of light produced by CBRlux or FFlux, allowing these reporters to
be used during macrophage infection to quantify bacterial
numbers present.
Thresholds of detection for mycobacteria during mouse
infection
Since both CBRlux and FFlux allow quantification of intracel-
lular mycobacteria, we examined their limits of detection for
mycobacteria during infection in animals. We infected mice
subcutaneously with 102 to 107 cfu of BCG expressing CBRlux or
FFlux to determine effects of infection on light production
(Figure 3). Although somewhat difficult to distinguish in whole
body images due to higher numbers of bacteria saturating the
dynamic range of the imager, the threshold of bacteria detected
(p,0.05) using this imaging system is 103 cfu for CBRlux and
104 cfu for FFlux. The number of bacteria present at each site was
confirmed after imaging by plating homogenized tissue for cfu and
correlates well with luminescence from 103 to 107 cfu (Figure 3B).
CBRlux displayed significantly higher luminescence than FFlux
Figure 1. Luminescence of mycobacteria during growth in
bacteriological media. Luminescent (FFlux and CBRlux) and non-
luminescent (pJDC89) BCG carrying the vector backbone display similar
growth rates in M-ADC-TW plus hygromycin (80 mg/ml) laboratory
medium (A). Luminescence for both firefly (FFlux) and click beetle red
(CBRlux) luciferase expressing BCG (BCG16 and BCG26) increases
steadily over time until approximately 12 days post-inoculation (B).
The correlation between luminescence and optical density of BCG
cultures expressing FFlux, CBRlux or the vector (pJDC89) alone (C). Data
and error bars represent the means and standard deviations,
respectively, of triplicate samples. Error bars are often too small to be
visible around the marker for the mean. RLU = relative light units. *
indicate data points with P,0.05 for FFlux vs. CBRlux.
doi:10.1371/journal.pone.0108341.g001
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for most bacterial numbers during subcutaneous infection. This
observation combined with the lower threshold of detection
observed with CBRlux suggests that luminescence produced by
CBRlux penetrates mammalian tissue more readily than FFlux,
most likely due to the longer wavelength of luminescence
produced by CBRlux as compared to FFlux [24,40].
Luciferases allow imaging of pulmonary infections in
mice
Most mycobacterial infections occur through the respiratory
route, which is a more difficult site to image optically due to the
greater tissue depth than for subcutaneous infections. Although a
103 cfu threshold of detection is promising to allow sensitive
tracking of mycobacteria during pulmonary infections, it is unclear
whether such low numbers could be detected in deeper tissues. We
tested this possibility by imaging mice infected intratracheally with
BCG expressing CBRlux and FFlux (Figure 4). We found that
both luciferases allowed the detection of 106 cfu of BCG in the
lungs of mice with short exposures of 1 min resulting in 100-fold
higher p/sec luminescence than background (Figure 4B). Al-
though both dorsal and ventral images could be used to detect the
presence of bacteria, ventral imaging resulted in higher lumines-
cence for both CBRlux and FFlux. Moreover, despite bacterial
numbers in the lungs for both CBRlux and FFlux strains being
comparable (,106 in both cases) luminescence was nearly 10-fold
higher for CBRlux than FFlux in both dorsal and ventral images.
The location of the source of luminescence was confirmed post-
mortem by collecting images after opening the chest cavities of the
mice (Figure 4C). All of the observed luminescence originated
from the lungs at 24 h post-infection. These observations indicate
that ventral imaging is more sensitive for tracking mycobacterial
pulmonary infections with imaging and luminescence produced by
CBRlux being greater than FFlux, making CBRlux a more
sensitive reporter for tracking pulmonary infections with myco-
bacteria.
Spectral characteristics of CBRlux and FFlux allow
simultaneous imaging
Since both CBRlux and FFlux can be used to track
mycobacterial infections in mice and they produce luminescence
that is maximal at different wavelengths, we tested whether their
signals could be separated using available algorithms for spectral
unmixing. Spectral unmixing involved first capturing multiple
images of the same animals, infected by both CBRlux and FFlux
subcutaneously, using a range of different emission filters on a
whole body optical imager (Figure 5A). We captured images of
infected mice in this manner using filters from 500 to 740 nm and
found that the maximum luminescence for FFlux is 540 to 600 nm
and for CBRlux is 600 to 620 nm (Figure 5C). Furthermore,
between 500 and 520 nm, there is almost no luminescence from
CBRlux and signal obtained for FFlux is near maximal, suggesting
that the spectral characteristics of these two luciferases will allow
their signal to be separated and quantified.
We examined the kinetics of light production for the luciferases
in mixed cultures to determine whether they competed differently
for the substrate, luciferin or their presence together would
interfere with levels of signal produced. We mixed cultures of
CBRlux and FFlux expressing strains in 1:1, 1:10 and 1:100 ratios
and measured luminescence in 96-well plates (Figure 5D). After a
rapid increase in light production to the maximum value within 10
s after addition of luciferin, there is a rapid decrease in the amount
of luminescence for the FFlux expressing BCG strain. Light
production continues to decrease over 2 minutes. Conversely, light
produced by CBRlux takes slightly longer (20–30 s) to reach
maximum values and stays at the maximum value for at least
2 minutes. We found that the mixing of the two luciferase
emissions results in a slight increase in overall light production but
that the kinetics of the light production were similar to that of the
major luciferase present. However, when the two luciferases were
mixed at a 1:1 ratio, the light production resembled a combination
of the two kinetic curves for each luciferase, with a lower initial
maximum as compared to FFlux alone, but an extended plateau
comparable to CBRlux. These results indicate that each luciferase
contributes relatively equally to the total luminescence produced
by mixed cultures and there is little interference between them or
competition for substrate when mixed together.
CBRlux and FFlux can be imaged simultaneously during
mixed infections
The ability to independently quantify two mycobacteria
expressing different luciferases during mixed infections would be
extremely valuable for evaluating competition assays with mutant
and wild type bacteria. We evaluated this theory by infecting mice
subcutaneously with mixtures of 10:1, 1:1 and 1:10 FFlux to
CBRlux expressing bacteria. At 24 h post-infection, infected mice
were imaged at a range of different wavelengths from 500 to
740 nm (Figure 6A) and the resulting signal at each infection site
spectrally unmixed to quantify the number of FFlux and CBRlux
bacteria present (Figure 6B, C). After spectral unmixing, infections
with FFlux and CBRlux expressing bacteria can be differentiated
and the luminescence observed at each site of infection correlated
with the numbers of each bacteria present. Composite images
were constructed to display the intensity of signal for each
luciferase at equally infected sites (1:1 ratio of FFlux:CBRlux) on
the animal as a combination of the luminescence present at that
site; whereas sites where there is a 10:1 ratio of bacteria (10:1
FFlux:CBRlux or 1:10 FFlux:CBRlux), the second luciferase is
observed as a smaller sector within the zone displaying lumines-
cence for the primary luciferase present. These observations
suggest that CBRlux and FFlux allow simultaneous quantification
of two strains of mycobacteria, even when the two strains are in a
mixed infection in mice. Two luminescence markers for imaging
have numerous applications in pathogenesis studies to follow
mutant and wild type strains, analysis of antimicrobial resistance
Figure 2. Luminescence from mycobacteria within macrophag-
es. Luminescence detected from firefly (FFlux) and click beetle red
(CBRlux) luciferase expressing BCG (BCG16 and BCG26) or BCG carrying
the vector (pJDC89) alone within J774A.1 macrophages. Infections in
macrophages were carried out with various multiplicities of infection
(MOI) from 0.1 to 100 bacteria per cell for 30 min and washed to
remove extracellular mycobacteria. Luciferin was added immediately
after infection (day 0) and on days 2 and 7 post-infection ,15 min
before luminescence measurements. Data and error bars represent the
means and standard deviations, respectively, of triplicate samples. RLU
= relative light units. * indicate data points with P,0.05 for luciferase
vs. pJDC89 expressing BCG at the same time point and same MOI.
doi:10.1371/journal.pone.0108341.g002
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when two populations are present differing in susceptibility, and
evaluation of both vaccine and challenge dose in vaccine efficacy
studies.
Optimization of luciferases for spectral imaging of co-
infections
The importance of CBRlux and FFlux for real-time analysis of
mycobacterial infections makes it a high priority to further
optimize their sensitivity to achieve the best thresholds of detection
possible. Two different versions of each CBRlux and FFlux gene
were used; one with the original DNA sequence and a second with
the amino acid codon usage optimized to mycobacterial preferred
amino acids (accession number JQ031640 for CBRlux and
JQ031641 for FFlux). We also utilized two promoters, the
mycobacteriaophage L5 promoter and the hsp60 promoter, both
of which are thought to drive high levels of transcription [42–45].
There was a significant increase in light production for both
CBRlux and FFlux in the strains where these genes were codon
optimized (Figure 7). In addition, hsp60 promoter expression
produced a stronger signal than expression from the L5 promoter.
Consistent with our observation that FFlux produced higher
luminescence than CBRlux in its native form, which might be due
to the presence of several rare codons in CBRlux, optimization of
CBRlux codon usage had a greater impact on light production
than optimization of FFlux. Similar to our in vitro results, codon
optimized CBRlux with optimized codon usage and expressed
from the hsp60 promoter resulted in higher luminescence than
CBRlux expressed from the L5 promoter (Figure 7C). Overall, the
optimized luciferase constructs and particularly the optimized
CBRlux display significantly higher luminescence than non-
optimized luciferases, suggesting that use of optimized luciferases
can improve thresholds of detection beyond that observed with
native luciferases.
CBRlux allows rapid evaluation of therapeutic efficacy
Since coleopteran luciferases require ATP for the production of
light, antimicrobial treatment of mice infected with luminescent
mycobacteria, resulting in reduced metabolic activity or death of
the bacteria, should result in a decrease in bioluminescence.
Having a rapid readout for effectiveness of candidate antimicro-
bials would greatly facilitate development of therapeutics against
mycobacterial infections, since obtaining results normally takes
over a month due to the time necessary for formation of colonies
on media to demonstrate a decrease in bacterial load. The ability
of antibiotics to reduce signal in CBRlux expressing mycobacteria
was examined by treating 104 BCG in culture medium with INH+
RIF for two days and comparing the inhibition of luminescence to
loss of cfu (Figure 8A, B). We found that inhibition of lumines-
cence was very similar to the level of killing observed by cfu assays,
though the percent was somewhat greater with cfu, suggesting that
luminescence may be a more sensitive measure of viable bacteria
persisting in a population than cfu. We evaluated the utility of
Figure 3. Correlation of bacterial numbers with luminescence. Whole body images of luminescence from BALB/C mice (2/group) inoculated
subcutaneously with 102 to 107 colony forming units (cfu) of BCG expressing click beetle red (CBRlux) or firefly (FFlux) luciferase (A) at 24 h post-
inoculation. After imaging, mice were sacrificed and cfu determined by plating homogenates of skin region from injection site. Bioluminescence from
each inoculation site correlates well with the number of bacteria present for both CBRlux and FFlux (B). Template for injection sites using different
numbers of cfu or PBS control (C). Data and error bars represent the means and standard deviations, respectively, of duplicate samples. Data are
expressed as total Flux in photons per second (p/sec). * indicate data points with P,0.05 for CBRlux vs. FFlux expressing BCG at the same inoculum.
doi:10.1371/journal.pone.0108341.g003
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CBRlux for evaluating therapeutics by infecting mice with 106 cfu
of BCG via the intratracheal route followed by treatment with
INH+RIF for six days post-infection (Figure 8C–F). We found that
luminescence was significantly lower in treated than untreated
animals from 24 h post-treatment. Since BCG does not replicate
in mice, the bacterial load decreased throughout the experiment,
as expected. However, the treated group displayed lower
luminescence at all time points and lower cfu at most time points.
Similar to observations in vitro, reductions in cfu appeared to be
more dramatic than luminescence, but the remaining lumines-
cence is likely due to the presence of bacteria that are not killed by
treatment. These observations demonstrate that CBRlux can be
used to evaluate therapeutic efficacy more rapidly than conven-
tional cfu-based assays both in vitro and during mycobacterial
infections in mice, suggesting that this reporter may be a more
sensitive measure of only partial sterilization than cfu in
therapeutic efficacy studies.
Discussion
Despite decades of study into TB and M. tuberculosis, little is
known regarding many aspects of mycobacterial disease progres-
sion and dissemination. Dissemination from the lung to pulmonary
lymph nodes and other organs is thought to be required for the
establishment of acquired immunity [55] but whether mycobac-
teria disseminate within host cells or extracellularly remains
controversial. Traditional methods for quantification of bacterial
burden in different organs requires sacrificing animals and plating
tissue homogenates for cfu determination, which is both time
consuming and costly due to the large number of animals required
and the one month or more required for colonies to form on
media. A growing body of literature suggests that photonic
imaging can now be utilized to estimate mycobacterial burdens
during infections in animals more rapidly [6,7,9,10,14,17–
19,25,26,30,56]. We have used FFlux and CBRlux to label
pathogenic mycobacteria and visualize infection in live animals.
Although the current study utilized BCG, the same vectors can be
used in M. tuberculosis, without any expected change in signal
produced, since these organisms are part of the tuberculosis-
complex and very closely related [57–59]. This strategy enables us
to follow the infection in individual mice throughout the entire
experiment, reducing the number of animals needed to conduct
statistically significant experiments. Each animal serves as its own
control, since each individual can be followed throughout the
Figure 4. Luminescence allows imaging during pulmonary infection. Whole body dorsal and ventral images of luminescence from click
beetle red (CBRlux) and firefly (FFlux) luciferase expressing BCG inoculated intratracheally into BALB/C mice (2/group) at 106 cfu (A). Two vector only
(pJDC89) control mice were imaged along with each set of two CBRlux or FFlux mice (vector controls on left). Data are expressed as total Flux in
photons per second (p/sec). Luminescence is greater with CBRlux than with FFlux and ventral imaging is more sensitive than dorsal imaging (B).
Imaging of mice post-mortem with open chest cavities demonstrates the luminescence signal originates from the lungs (C). Data and error bars
represent the means and standard deviations, respectively, of duplicate samples. * indicate data points with P,0.05 between data indicated by
horizontal bars.
doi:10.1371/journal.pone.0108341.g004
Dual Bioluminescence in Mycobacteria
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e108341
entire experiment, reducing the experimental variability usually
due to animal-to-animal differences. Theoretically, imaging could
ultimately obviate the need to sacrifice animals unless localization
to specific tissues must be confirmed, cellular level analyses are
needed or interpretation is complicated by a change in the
correlation between cfu and signal. Animals can be monitored
over time with imaging and only sacrificed at key time points for
more detailed analyses.
We took advantage of existing luminescent markers, CBRlux
and FFlux, to label BCG by expressing the luciferases from
plasmids. The two promoters used in this study show little
difference in luminescence but we were able to greatly increase the
signal by optimizing the codon usage in the CBRlux and FFlux
genes for that preferred by mycobacteria, similar to codon
optimization of luciferases described in other studies [17,18].
Expression of either luciferase does not appear to cause growth
defects in these bacteria and signal production remains at a
relatively constant level up to seven days in the absence of the
selective marker for the expression plasmid, even when bacteria
are grown in a macrophage culture. These findings show that our
constructs offer robust expression systems for CBRlux and FFlux
and they have little or no detrimental effect on mycobacterial
growth. Interestingly, background luminescence is extremely low
with bacteria containing vector alone, but in both macrophages
and mouse tissues, background with vector alone is higher,
decreasing the signal-to-noise ratios and, thereby, increasing the
Figure 5. Spectral characteristics of firefly and click beetle red luciferase. Collection of whole body images of BALB/C mice (2/group)
infected subcutaneously with 106 cfu of BCG expressing click beetle red (CBRlux) or firefly (FFlux) luciferase at defined wavelengths between 540 nm
and 720 nm demonstrates that very little luminescence is obtained from CBRlux at short wavelengths and, similarly, less is obtained for FFlux at
longer wavelengths (A). Template map for subcutaneous inoculation of BCG strains and PBS control (B). Quantitation of total Flux (p/sec) at different
wavelengths for areas with CBRlux of FFlux indicates that luminescence from each reporter can be spectrally separated (C). Comparing luminescence
kinetics obtained with mixed cultures of 104 total cfu CBRlux and FFlux expressing BCG at ratios from 1:1 to 1:100 shows that the kinetic curve of a
mixed culture resembles that of the luciferase that is at higher numbers in the culture. Furthermore, at the similar numbers (1:1) the kinetic curve
appears to be a mix between the two curves for the luciferases. Since the kinetic curves are directly relates to the numbers of each strain present, it is
likely that these luciferases compete similarly for available substrate (D). Luminescence was measured using a plate reader after injecting 50 ml of
2 mM luciferin. Measurements began 10 s after adding luciferin and were taken every 10 s up to 5 min.
doi:10.1371/journal.pone.0108341.g005
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Figure 6. Spectral unmixing of luminescence allows quantitation of mixed bacterial infections. Whole body images were obtained from
BALB/C mice (2/group) subcutaneously infected with a total of 107 cfu BCG mixed at different ratios from 1:10 to 1:1 expressing click beetle red
(CBRlux) or firefly (FFlux) luciferase at defined wavelengths from 520 nm to 720 nm demonstrates ability to quantitatively separate signal from
CBRlux and FFlux in mixed infections, similar to those seen in mixed cultures (A). Normalized quantification of signal at defined wavelengths after
spectral unmixing for FFlux or CBRlux (left panel) and map of subcutaneous inoculation sites on mice (right panel) for imaging (B). After unmixing
signal at each injection site correlates with the number of FFlux or CBRlux bacteria present (C). The composite image (on the right) shows green for
quantitative FFlux signal, red for CBRlux signal and orange at positions of co-localization of both CBRlux and FFlux signals.
doi:10.1371/journal.pone.0108341.g006
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Figure 7. Codon optimized luciferases produce more light than non-optimized luciferases. BCG (104 cfu) expressing wild type click beetle
red (CBRlux) or firefly (FFlux) luciferases or the same luciferases synthetically optimized for mycobacterial codon usage (opt) were examined in liquid
culture for light production over time in the presence of 2 mM luciferin (A, B). Results shown are for the individual strains of each type selected for
maximal luminescence as described in the methods. BCG containing the vector alone (pJDC89) was used as a control. Both the L5 and hsp60
promoters were examined with the codon optimized luciferases to evaluate which promoter results in the greatest light production. Whole body
images of BALB/C mice (2/group) subcutaneously infected with 106 cfu of the same BCG strains show similar results to those found in liquid culture
where codon optimized luciferases produce greater luminescence (C). A map of subcutaneous inoculation sites on mice is shown in the right panel.
Quantitation of each inoculation site for total Flux photons per second (p/sec) indicates that the codon optimized CBRlux expressed from hsp60
emits the most light (D). Data and error bars represent the means and standard deviations, respectively, of two mice. ** indicates p,0.01 as
compared to FFlux in the same construct.
doi:10.1371/journal.pone.0108341.g007
Dual Bioluminescence in Mycobacteria
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e108341
number of bacteria required to obtain significant signal, in the
presence of mammalian cells. Despite this issue, we can detect as
few as 103 cfu during mouse subcutaneous infection significantly
above background, a very promising threshold of detection.
Theoretically, these constructs should be expressed well in any
mycobacterial species, including different mutant backgrounds,
Figure 8. Codon optimized click beetle red luciferase (CBRlux) allows rapid therapeutic evaluation. Percent inhibition of light
production (A) and bacterial killing (B) for 104 of BCG expressing codon optimized CBRlux (optCBRlux) in the presence of different concentrations of
isoniazid (INH) plus rifampin (RIF) during culture in bacterial media after 24 (day 1) or 48 h (day 2) as compared to the absence of antimicrobials.
Whole body imaging during pulmonary infection in BALB/C mice (4/group) with 46106 cfu of BCG expressing optCBRlux after 24 and 48 hr treatment
with 10 mg/kg INH+RIF results in a reduction in luminescence (C). Quantitation of the percentage of the initial luminescence as compared to each
time point out to six days post-treatment confirms the reduced luminescence in treated animals (D). Similarly, ex-vivo imaging of lungs at 2 days to
confirm luminescence observed in whole body images is derived from the lungs and is reduced after antibiotic treatment (E). Untreated and treated
panels for lung images are indicated in panel C. Correlation of luminescence with cfu present was confirmed by plating homogenates from the same
animals at each time point (F). Data and error bars represent the means and standard deviations, respectively, of four mice. * indicates p,0.05 and **
indicates p,0.01 as compared to treated group at the same time point.
doi:10.1371/journal.pone.0108341.g008
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offering a simple method to label mycobacteria for use of in vivo
imaging in pathogenesis, as well as vaccine and therapeutic
studies.
Two different luminescence reporters, CBRlux and FFlux, with
different emission spectra, allow dual bioluminescent labeling to
study mycobacterial infections in vivo, similar to the system
described for Escherichia coli [60]. The luminescence from BCG
expressing FFlux or CBRlux can be localized to the site of
infection with detection limits as low as 103 bacteria by
subcutaneous inoculation. Thus, the lower limits of detection
using bioluminescence are lower than those found for in vivo
imaging of mycobacteria using fluorescent markers [6]. This
improvement in limits of detection reduces the number of bacteria
required for detection, thus facilitating the use of more clinically
relevant infectious doses, which is particularly important for
infections with M. tuberculosis. However, since subcutaneous
inoculations were used to determine this threshold of detection, it
is likely that pulmonary infections withM. tuberculosis will require
somewhat higher inocula to produce similar signal due to
attenuation from increased mammalian tissue depth. Overall,
CBRlux and FFlux, with emission maxima in the far red window,
offer less signal loss due to light absorption and scattering in tissue,
making them more compatible with in vivo imaging [39].
Furthermore, because these two luciferases use the same luciferin
substrate, they can be imaged and discriminated simultaneously.
We are able separate the two signals spectrally, allowing the strains
that express them to be tracked and quantified. These luciferases
will allow us to perform competition assays between mutant and
wild type strains in the same animal. Dual color luminescence has
been described with red and a green luciferases that can be
spectrally separated in other systems [60,61], but have not been
used in mycobacteria. Our study supports the potential for
multiple luciferases to be imaged simultaneously in vitro and in
vivo using unmixing algorithms. A study dissecting the role of the
adaptive immune response described the use luxAB labelled BCG
in a RAG-22/2/ccR
2/2 mouse background [30]. In this study,
wild type CD90+ T-cells were used to complement the mutant
mice and reduce luminescence to undetectable levels by 10 weeks.
Our dual luciferase system could be used to analyze immunolog-
ical events during bacterial infection in real time by labeling a
subset of immune cells in conjunction with bioluminescent
bacteria. This strategy will allow us to dissect both the bacterial
and host pathways involved in mycobacterial pathogenesis.
Analysis of multiple mycobacterial strains or both the pathogen
and host in the same animal are only possible using multiple
luminescent reporters that can be spectrally separated. It is
important to remember that, due to the overlap in the wavelengths
of detection for CBRlux and FFlux, it may be challenging to
always accurately and sensitively discriminate them, particularly
when signal levels are extremely low for one or the other of these
luciferases. Further studies are needed to identify additional
luciferases that may be used in this manner, possibly with more
easily separated spectral characteristics, allowing analysis of at least
three strains or multiple host elements during infection.
We used our luminescent mycobacterial strains to determine the
effect of antibiotic treatment on light production both in vitro and
during infection. Similar to previous studies [12–16,18,27,31,36–
38], the level of bioluminescence is sensitive to increased amounts
of antibiotics, suggesting that our constructs could be used to
rapidly screen for efficacy of new antibiotics in high-throughput
studies. Also, using in vivo imaging for infections and antibiotic
treatment, we can verify the efficacy of antimicrobials that are
effective in vitro, consistent with studies from other groups [38].
One caveat of the current study is that plasmids were used, which,
although we observed a good correlation with cfu for seven days in
the absence of selection, may not allow longer-term studies in vivo
due to plasmid loss. This issue could be overcome through the use
of integrating plasmids that are much more stable or placement of
the constructs into specific sites in the chromosome by allelic
exchange. Despite these caveats, these data demonstrate that
luciferases can be exceedingly valuable for analysis of novel
prevention and treatment strategies for mycobacterial infections.
We found that CBRlux and FFlux serve as highly sensitive
luminescent reporters for mycobacteria, allowing determination of
spatio-temporal distribution of bacteria within mice during
infection. CBRlux and FFlux signals can be spectrally separated
for simultaneous quantitative analysis of two different bacterial
strains or bacteria along with a host cell type or marker. These
luciferases can be used to sensitively detect of bacteria in
pulmonary infections and can be used to evaluate therapeutic
efficacy in real time. Moreover, this approach provides a novel
strategy to facilitate dissecting mycobacterial pathogenesis, as well
as improved understanding of therapeutic and vaccine studies.
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